Kayayyaki

1.Don bincika ko adenosine diphosphate (ADP) -wanda aka samu adenosine zai iya hana haɗuwar platelet, musamman ma a gaban P2Y₁₁ antagonist, inda za a hana tasirin ADP a mai karɓar P2Y₁₂. peptide ta hanyar kirga platelet a cikin plasma mai arzikin platelet (PRP) da duka jini a gaban ADP da P2Y₁₂ antagonists cangrelor, prasugrel aiki metabolite, da ticagrelor.A gaban P2Y₁₁ antagonist, preincubation na PRP tare da ADP hana tarawa;An kawar da wannan tasirin ta hanyar adenosine deaminase.Babu hana tarawa da ya faru a cikin jini gaba ɗaya sai dai lokacin da aka ƙara dipyridamole don hana ɗaukar adenosine cikin erythrocytes.Sakamakon ADP a cikin PRP da dukan jini an yi amfani da su ta hanyar amfani da adenosine kuma suna da alaƙa kai tsaye da canje-canje a cikin cAMP (kimantawa ta hanyar vasodilator-stimulated phosphoprotein phosphorylation).Duk sakamakon sun kasance iri ɗaya ba tare da la'akari da ant agonist na P2Y₁₁ da aka yi amfani da su ba.ADP yana hana tarawar platelet a gaban mai adawa da P2Y₁₂ ta hanyar tuba zuwa adenosine.Hani yana faruwa a cikin PRP amma ba a cikin jini duka ba sai lokacin da aka hana adenosine.Babu wani daga cikin masu adawa da P2Y₁₁ da aka yi nazari da ya kwaikwayi tasirin dipyridamole a cikin gwaje-gwajen da aka yi.

2.ADP ana la'akari da agonist mai rauni na platelet saboda iyakanceccen amsawar tattarawa da yake haifar da shi a cikin vitro a matakan ilimin lissafi na extracellular Ca (2+) [(Ca (2+)) (o) ].Ragewa [Ca (2+)] (o) yana haɓaka haɓakar haɓakar ADP, tasirin da aka danganta da haɓakar haɓakar thromboxane A (2).Wannan binciken yayi nazarin rawar ectonucleotidases a cikin [Ca (2+)] (o) -dogara na kunna platelet.Rage [Ca (2+)] (o) daga millimolar zuwa matakan micromolar da aka canza ADP (10 μmol/l) -haɗaɗɗen tarin platelet daga mai wucewa zuwa amsa mai dorewa a cikin plasma mai wadatar platelet da dakatarwa.Kashe thromboxane A (2) samar da aspirin ba shi da tasiri akan wannan [Ca (2+)] (o) -dogara.Rigakafin lalacewar ADP ya kawar da bambance-bambance tsakanin ƙananan da ilimin lissafi [Ca (2+)] (o) yana haifar da haɓaka mai ƙarfi da ci gaba a cikin yanayi biyu.Ma'auni na ADP na waje ya nuna raguwar raguwa a cikin duka plasma da apyrase-dauke da saline a micromolar idan aka kwatanta da millimolar [Ca (2+)] (o).Kamar yadda aka ruwaito a baya, an haɓaka tsararrun thromboxane A (2) a ƙananan [Ca (2+)] (o), duk da haka wannan ya kasance mai zaman kanta daga ayyukan ectonucleotidase (.) P2Y antagonists antagonists cangrelor da MRS2179 sun nuna bukatar P2Y (12) masu karɓa. don ci gaba da tattarawar ADP, tare da ƙaramin aiki don P2Y(1) .A ƙarshe, Ca (2+) -dogara ectonucleotidase aiki shine babban abin da ke ƙayyade girman haɗuwar platelet zuwa ADP kuma dole ne a sarrafa shi don nazarin kunnawa mai karɓa na P2Y.